Merck’s third-quarter sales grew 5%, while non-GAAP EPS fell 3%. Management nudged up the low end of 2026 revenue guidance, now implying 3%-4% revenue growth, and raised non-GAAP EPS guidance to a range of $2.77-$2.82. Shares rose 4% on Oct. 29.
Keytruda's leadership position in immuno-oncology, buoyed by a first-mover advantage in first-line non-small cell lung cancer, could become even further entrenched as Merck and other firms test new combinations with the drug.
The US patent loss on Keytruda in 2028 is concerning, given the high sales contribution of the drug (49% of 2025 sales).
|
Metric
|
MRK
|
LLY
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 45.59 | 43.62 | 9.82 |
Price/Book Value | 8.61 | 30.40 | 2.00 |
Price/Sales | 5.37 | 14.22 | 2.69 |
Price/Cash Flow | 16.38 | 33.96 | 11.14 |
|
Metric
|
MRK
|
LLY
|
PFE
|
|---|---|---|---|
Quick Ratio | 0.71 | 0.64 | 0.85 |
Current Ratio | 1.32 | 1.39 | 1.27 |
Interest Coverage | 4.28 | 33.96 | 2.36 |
|
Metric
|
MRK
|
LLY
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | 6.27% | 28.08% | 8.46% |
Return on Equity (Normalized) | 16.68% | 114.41% | 19.70% |
Return on Invested Capital (Normalized) | 9.74% | 46.92% | 12.66% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|#P>kf&X | LOCK|h!f | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|qwL%&w& | LOCK|?^k | $662B | |||
| AbbVie Inc
ABBV
| LOCK|f&^jWp? | LOCK|&Q% | $514B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|@$D!&hs | LOCK|#L | $388B | |||
| Novartis AG ADR
NVS
| LOCK|lmQpD#K? | LOCK|s&x | $302B | |||
| AstraZeneca PLC
AZN
| LOCK|?xTN>&Q | LOCK|b> | $270B | |||
| Amgen Inc
AMGN
| LOCK|?vDzs@@ | LOCK|Fp | $249B | |||
| Gilead Sciences Inc
GILD
| LOCK|T%Ln&D | LOCK|w< | $205B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|R#NP!#n | LOCK|$jr | $171B |
United States